High Dose Rosuvastatin for PCI Patients

Background

Rosuvastatin 40 mg loading therapy before percutaneous coronary intervention (PCI) has been shown to significantly reduce the incidence of periprocedural myocardial infarction (MI) and 30-day major adverse cardiac events (MACE) in patients with non-ST-segment elevation ACS.
However, long-term effects of statin loading therapy on patients with ACS have not been evaluated.

Objective

To investigate the effect on long term clinical outcomes of single high-dose rosuvastatin therapy administered before PCI in patients with ACS.

Patient Profile

445 patients with non-ST-segment elevation ACS

Study Groups

Patients were randomized to no statin pretreatment group (control group) or to the group receiving 40 mg rosuvastatin loading therapy before PCI (rosuvastatin group).

Primary Endpoint

Occurrence of MACE, including cardiac death, non-fatal MI, non-fatal stroke and any ischemia-driven revascularization

Study Duration

12 months

Results

The composite primary end point of death, non-fatal MI, non-fatal stroke and revascularization occurred in 20.5% patients is control group as compared to 9.8% patients in rosuvastatin group (p=0.002).

The incidence of death and non-fatal MI was 3-fold greater in the control group as compared to rosuvastatin group (HR 3.71; P=0.021).

Conclusion

High dose rosuvastatin loading before PCI significantly improved 12-month clinical outcomes in patients with ACS who underwent an early invasive strategy.

Int J Cardiol., Published online, June 2010

0